The Immune System and Inflammation in Breast Cancer

Overview

Journal Mol Cell Endocrinol

Specialties Cell Biology
Endocrinology
Molecular Biology

Date 2013 Jun 25

PMID 23791814

Citations 122

Authors

Xinguo Jiang

David J Shapiro

Affiliations

Soon will be listed here.

Abstract

During different stages of tumor development the immune system can either identify and destroy tumors, or promote their growth. Therapies targeting the immune system have emerged as a promising treatment modality for breast cancer, and immunotherapeutic strategies are being examined in preclinical and clinical models. However, our understanding of the complex interplay between cells of the immune system and breast cancer cells is incomplete. In this article, we review recent findings showing how the immune system plays dual host-protective and tumor-promoting roles in breast cancer initiation and progression. We then discuss estrogen receptor α (ERα)-dependent and ERα-independent mechanisms that shield breast cancers from immunosurveillance and enable breast cancer cells to evade immune cell induced apoptosis and produce an immunosuppressive tumor microenvironment. Finally, we discuss protumorigenic inflammation that is induced during tumor progression and therapy, and how inflammation promotes more aggressive phenotypes in ERα positive breast cancers.

Citing Articles

Exploring the synergistic effects of vitamin D and synbiotics on cytokines profile, and treatment response in breast cancer: a pilot randomized clinical trial.

Tirgar A, Rezaei M, Ehsani M, Salmani Z, Rastegari A, Jafari E Sci Rep. 2024; 14(1):21372.

PMID: 39266591 PMC: 11393349. DOI: 10.1038/s41598-024-72172-x.

MDM2 inhibitors in cancer immunotherapy: Current status and perspective.

Zeng Q, Zeng S, Dai X, Ding Y, Huang C, Ruan R Genes Dis. 2024; 11(6):101279.

PMID: 39263534 PMC: 11388719. DOI: 10.1016/j.gendis.2024.101279.

Combined influence of nutritional and inflammatory status and breast cancer: findings from the NHANES.

Gao X, Qi J, Du B, Weng X, Lai J, Wu R BMC Public Health. 2024; 24(1):2245.

PMID: 39160507 PMC: 11331661. DOI: 10.1186/s12889-024-19727-9.

Association of tumor-infiltrating lymphocytes with clinical outcomes in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a systematic review and meta-analysis.

de Moraes F, Cavalcanti Souza M, Sano V, Moraes R, Melo A Clin Transl Oncol. 2024; .

PMID: 39154313 DOI: 10.1007/s12094-024-03661-8.

Oxidative stress-related genes score predicts prognosis and immune cell infiltration landscape characterization in breast cancer.

Liu D, Fang L Heliyon. 2024; 10(13):e34046.

PMID: 39071696 PMC: 11283013. DOI: 10.1016/j.heliyon.2024.e34046.

References

Hamidullah , Changkija B, Konwar R . Role of interleukin-10 in breast cancer. Breast Cancer Res Treat. 2011; 133(1):11-21. DOI: 10.1007/s10549-011-1855-x. View

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

Kirk G, Merlo C, O Driscoll P, Mehta S, Galai N, Vlahov D . HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis. 2007; 45(1):103-10. PMC: 4078722. DOI: 10.1086/518606. View

Roberti M, Rocca Y, Amat M, Pampena M, Loza J, Colo F . IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients. Breast Cancer Res Treat. 2012; 136(3):659-71. DOI: 10.1007/s10549-012-2287-y. View

de Palma M, Venneri M, Galli R, Sergi Sergi L, Politi L, Sampaolesi M . Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell. 2005; 8(3):211-26. DOI: 10.1016/j.ccr.2005.08.002. View

Zhu P, Baek S, Bourk E, Ohgi K, Garcia-Bassets I, Sanjo H . Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell. 2006; 124(3):615-29. DOI: 10.1016/j.cell.2005.12.032. View

Terry M, Gammon M, Zhang F, Tawfik H, Teitelbaum S, Britton J . Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA. 2004; 291(20):2433-40. DOI: 10.1001/jama.291.20.2433. View

Basu S, Nachat-Kappes R, Caldefie-Chezet F, Vasson M . Eicosanoids and adipokines in breast cancer: from molecular mechanisms to clinical considerations. Antioxid Redox Signal. 2012; 18(3):323-60. DOI: 10.1089/ars.2011.4408. View

Xu D, Takeshita F, Hino Y, Fukunaga S, Kudo Y, Tamaki A . miR-22 represses cancer progression by inducing cellular senescence. J Cell Biol. 2011; 193(2):409-24. PMC: 3080260. DOI: 10.1083/jcb.201010100. View

10.

Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V . Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009; 69(5):2000-9. DOI: 10.1158/0008-5472.CAN-08-2360. View

11.

Huang B, Pan P, Li Q, Sato A, Levy D, Bromberg J . Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006; 66(2):1123-31. DOI: 10.1158/0008-5472.CAN-05-1299. View

12.

Steding C, Wu S, Zhang Y, Jeng M, Elzey B, Kao C . The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. Immunology. 2011; 133(2):221-38. PMC: 3088984. DOI: 10.1111/j.1365-2567.2011.03429.x. View

13.

Konjevic G, SPUZIC I . Stage dependence of NK cell activity and its modulation by interleukin 2 in patients with breast cancer. Neoplasma. 1993; 40(2):81-5. View

14.

Bidwell B, Slaney C, Withana N, Forster S, Cao Y, Loi S . Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med. 2012; 18(8):1224-31. DOI: 10.1038/nm.2830. View

15.

Drabsch Y, Ten Dijke P . TGF-β signaling in breast cancer cell invasion and bone metastasis. J Mammary Gland Biol Neoplasia. 2011; 16(2):97-108. PMC: 3095797. DOI: 10.1007/s10911-011-9217-1. View

16.

Lin E, Nguyen A, Russell R, Pollard J . Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001; 193(6):727-40. PMC: 2193412. DOI: 10.1084/jem.193.6.727. View

17.

Kummer J, Micheau O, Schneider P, Bovenschen N, Broekhuizen R, Quadir R . Ectopic expression of the serine protease inhibitor PI9 modulates death receptor-mediated apoptosis. Cell Death Differ. 2007; 14(8):1486-96. DOI: 10.1038/sj.cdd.4402152. View

18.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

19.

Chen E, Smyth E . COX-2 and PGE2-dependent immunomodulation in breast cancer. Prostaglandins Other Lipid Mediat. 2011; 96(1-4):14-20. PMC: 4031099. DOI: 10.1016/j.prostaglandins.2011.08.005. View

20.

Ryan B, Konecny G, Kahlert S, Wang H, Untch M, Meng G . Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol. 2006; 17(4):597-604. DOI: 10.1093/annonc/mdj121. View